โšกYour ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency

Sponsored by Grace Science, LLC

Quick Self-Assessment

See if you qualify and express your interest

Preparing your pre-screening questions...

Current Status

Recruiting

Auto-verified from ClinicalTrials.gov

Verified Apr 24, 2025

Phase

Clinical Trial

Sponsor

Grace Science, LLC

Enrollment Target

6

Start Date

Feb 2024

๐Ÿ“Š
1 of 6 participants interested
17% interest

Express Your Interest Today

Interested in learning more? Complete the form below.

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Advance Medical Science

    Contribute to groundbreaking research

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel (varies by study)

  • Help Others

    Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3In-person assessment if eligible
  4. 4Begin participation

About This Study

A non-randomized, open-label, dose escalation study of a single intracerebroventricular (ICV) administration of a gene replacement therapy in subjects who are 2 to 18 years old with NGLY1 Deficiency.

Who Can Participate

Inclusion Criteria

Patients must be 2 to 18 years of age, inclusive, at the time of signing the informed consent form (ICF)
Patients with a documented diagnosis of NGLY1 Deficiency based on detection of biallelic variants in the NGLY1 gene via molecular genetic sequencing
Elevated GNA levels may be considered alongside genetic sequencing data and other clinical data to assist with diagnosis confirmation
Patients with two or more of the following clinical features typical of NGLY1 Deficiency: 1. Global developmental delay and/or intellectual disability 2. Hyperkinetic movement disorder 3. Transient elevation of transaminases 4. (Hypo)alacrima 5. Peripheral neuropathy
For patients with epilepsy who require anti-seizure medications for seizure control: must be on a stable regimen for 28 days prior to enrollment
Patients willing and capable per investigator opinion to comply with study procedures and requirements
Females of childbearing potential must have a nega

โ“ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

๐Ÿ“‹

Study Type

INTERVENTIONAL

๐Ÿ‘ฅ

Target Enrollment

6 participants

๐ŸŽ‚

Age Range

2 Years - 18 Years

โšง

Gender

ALL

๐Ÿข

Sponsor

Grace Science, LLC

Study Locations

Choose your preferred location or select flexible during enrollment

RECRUITING

Oakland

California

Location available
View Oakland location page
RECRUITING

New York

New York

Location available
View New York location page
RECRUITING

Houston

Texas

Location available
View Houston location page

Frequently Asked Questions

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

๐Ÿ”’ Secure ยท ๐Ÿฅ Expert Care

Find More Interstitial Cystitis Trials by City

Browse all interstitial cystitis clinical trials in these cities โ€” not just this study.

Looking for NGLY1 Deficiency Treatment in Oakland?

Join others in California exploring innovative treatment options through clinical research

NGLY1 Deficiency Treatment Options in Oakland, California

If you're searching for NGLY1 Deficiency treatment in Oakland, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Oakland, New York, Houston and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with NGLY1 Deficiency. All study-related care is provided at no cost to participants.

Local Sites
3 locations in California
Now Enrolling
Up to 6 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for NGLY1 Deficiency?

Potential Benefits

  • โœ“Access to new treatment approaches before public availability
  • โœ“Close monitoring by experienced medical professionals
  • โœ“Study-related care provided at no cost
  • โœ“Contribute to medical research for NGLY1 Deficiency

What to Expect

  • โ†’Initial screening to determine eligibility
  • โ†’Regular check-ups and monitoring visits
  • โ†’Possible compensation for time and travel
  • โ†’You can withdraw at any time

Frequently Asked Questions About This NGLY1 Deficiency Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06199531. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.